ClinicalTrials.gg
CompletedNCT00751621Updated Apr 2, 2014Results posted

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

A Phase 3 interventional study of IgPro20 in Primary Immunodeficiency (PID), sponsored by CSL Behring. Completed at 13 sites in 8 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-02.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
4th of 13
40 · median 25
Started
2008
with 2 others
Phase 3
9 of 14
none open now
Registered
7th of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2008, is one of 9 in phase 3, and was the 7th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.

03

Conditions studied

  • Primary Immunodeficiency (PID)

Keywords

  • Immune globulin subcutaneous
  • SCIG
  • primary immunodeficiency
  • PID
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common variable immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiencies (ESID), or X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or autosomal recessive agammaglobulinemia who have participated in the study ZLB06_001CR and who have tolerated IgPro well
  • Written

Exclusion criteria

Exclusion Criteria:

  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined as total urine protein concentration > 0.2g/L)
  • Other significant medical conditions that could increase the risk to the subject
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study
  • Participation in a study with an medicinal product within three months prior to enrollment, except for ZLB06_001CR
  • Evidence of uncooperative attitude
  • Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study
  • Subjects who are employees at the investigational site, relatives or spouse of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    IgPro20

    Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).

    Biological: IgPro20

Interventions

  • BiologicalIgPro20

    Also known as: IgG with Proline (IgPro), Hizentra

06

What researchers measure

Primary outcomes

  1. Total Serum IgG Trough Levels

    The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.

    Time frame: Up to 42 months

Secondary outcomes

  1. Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)

    The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by the Medical Monitor and Investigator to determine if the event fulfilled the predefined criteria for SBIs.

    Time frame: Up to 42 months

  2. Annualized Rate of Infection Episodes

    The annualized rate was based on the total number of infection episodes occurring during the study divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Up to 42 months

  3. Number of Infection Episodes

    Total number of infections for the specified analysis population

    Time frame: Up to 42 months

  4. Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

    The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Up to 42 months

  5. Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

    Total number of days out of work / school / kindergarten / day care or unable to perform normal activities due to infections, for the specified analysis population

    Time frame: Up to 42 months

  6. Annualized Rate of Hospitalization Due to Infections

    The annualized rate was based on the total number of days of hospitalization due to infections and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Up to 42 months

  7. Number of Days of Hospitalization Due to Infections

    Total number of days of hospitalization due to infections for the specified analysis population

    Time frame: Up to 42 months

  8. Use of Antibiotics for Infection Prophylaxis and Treatment

    Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.

    Time frame: Up to 42 months

  9. Health Related Quality of Life (Short Form 36 Health Survey)

    The Short Form 36 Health Survey (SF-36) is a 36-item questionnaire that measures generic health concepts that are relevant across age, disease, and treatment groups. The questions are grouped into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100, with higher scores indicating a better health state.

    Time frame: At baseline and at the last available post-baseline observation for each subject (up to 42 months)

  10. Clinically Relevant Changes in Vital Signs From Baseline to the Completion Visit.

    The total number of subjects with clinically relevant changes in vital signs from baseline to the completion visit. Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.

    Time frame: At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).

  11. Clinically Significant Abnormal Changes in Routine Laboratory Parameters Between Baseline and the Completion Visit.

    The total number of subjects with clinically significant abnormal changes in routine laboratory parameters between baseline and the completion visit. Routine laboratory parameters included haematology, serum chemistry and urinalysis.

    Time frame: At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).

  12. Rate, Severity and Relatedness of Any Adverse Events (AEs) Per Infusion

    The rate of AEs was the number of AEs over the number of infusions administered. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.

    Time frame: Up to 42 months

07

Results

Posted Jan 25, 2013

Participant flow

Subjects who had previously participated in the pivotal study ZLB06_001CR (NCT00542997) were enrolled in the extension study ZLB07_002CR.

Participant flow — Overall Study
MilestoneIgPro20
Started40
Completed36
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Subject moved to another country1
Withdrew: Poor adherence to asthma treatment1

Outcome measures

PrimaryTotal Serum IgG Trough Levels

The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.

Time frame:
Up to 42 months
Reported as:
Mean · g/L
Total Serum IgG Trough Levels
g/LIgPro20
Total Serum IgG Trough Levels7.97 ± 1.171
SecondaryAnnualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)

The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by the Medical Monitor and Investigator to determine if the event fulfilled the predefined criteria for SBIs.

Time frame:
Up to 42 months
Reported as:
Number · SBIs per subject year
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)
SBIs per subject yearIgPro20
Annualized Rate0.048
Upper 1-sided 99% Confidence Limit0.1252
SecondaryAnnualized Rate of Infection Episodes

The annualized rate was based on the total number of infection episodes occurring during the study divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Up to 42 months
Reported as:
Number · infection episodes per subject year
Annualized Rate of Infection Episodes
infection episodes per subject yearIgPro20
Annualized Rate of Infection Episodes3.334 (2.993 to 3.703)
SecondaryNumber of Infection Episodes

Total number of infections for the specified analysis population

Time frame:
Up to 42 months
Reported as:
Number · infection episodes
Number of Infection Episodes
infection episodesIgPro20
Number of Infection Episodes349
SecondaryAnnualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Up to 42 months
Reported as:
Number · days per subject year
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
days per subject yearIgPro20
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections6.773
SecondaryNumber of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections

Total number of days out of work / school / kindergarten / day care or unable to perform normal activities due to infections, for the specified analysis population

Time frame:
Up to 42 months
Reported as:
Number · days
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
daysIgPro20
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections706
SecondaryAnnualized Rate of Hospitalization Due to Infections

The annualized rate was based on the total number of days of hospitalization due to infections and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Up to 42 months
Reported as:
Number · days per subject year
Annualized Rate of Hospitalization Due to Infections
days per subject yearIgPro20
Annualized Rate of Hospitalization Due to Infections1.055
SecondaryNumber of Days of Hospitalization Due to Infections

Total number of days of hospitalization due to infections for the specified analysis population

Time frame:
Up to 42 months
Reported as:
Number · days
Number of Days of Hospitalization Due to Infections
daysIgPro20
Number of Days of Hospitalization Due to Infections110
SecondaryUse of Antibiotics for Infection Prophylaxis and Treatment

Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.

Time frame:
Up to 42 months
Reported as:
Number · days per subject year
Use of Antibiotics for Infection Prophylaxis and Treatment
days per subject yearIgPro20
Use of Antibiotics for Infection Prophylaxis and Treatment72.13
SecondaryHealth Related Quality of Life (Short Form 36 Health Survey)

The Short Form 36 Health Survey (SF-36) is a 36-item questionnaire that measures generic health concepts that are relevant across age, disease, and treatment groups. The questions are grouped into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100, with higher scores indicating a better health state.

Time frame:
At baseline and at the last available post-baseline observation for each subject (up to 42 months)
Reported as:
Median · score on a scale
Health Related Quality of Life (Short Form 36 Health Survey)
score on a scaleIgPro20 - At BaselineIgPro20 - At End of Study
Physical Functioning95.0 (75.0 to 100.0)100.0 (20.0 to 100.0)
Role-physical100.0 (18.8 to 100.0)100.0 (37.5 to 100.0)
Role-emotional100.0 (25.0 to 100.0)100.0 (25.0 to 100.0)
Social Functioning100.0 (62.5 to 100.0)100.0 (37.5 to 100.0)
Bodily Pain84.0 (22.0 to 100.0)84.0 (22.0 to 100.0)
Mental Health85.0 (55.0 to 95.0)80.0 (35.0 to 95.0)
Vitality65.6 (31.3 to 81.3)75.0 (18.8 to 100.0)
General Health52.0 (15.0 to 82.0)54.5 (20.0 to 92.0)
SecondaryClinically Relevant Changes in Vital Signs From Baseline to the Completion Visit.

The total number of subjects with clinically relevant changes in vital signs from baseline to the completion visit. Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.

Time frame:
At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).
Reported as:
Number · participants
Clinically Relevant Changes in Vital Signs From Baseline to the Completion Visit.
participantsIgPro20
Clinically Relevant Changes in Vital Signs From Baseline to the Completion Visit.0
SecondaryClinically Significant Abnormal Changes in Routine Laboratory Parameters Between Baseline and the Completion Visit.

The total number of subjects with clinically significant abnormal changes in routine laboratory parameters between baseline and the completion visit. Routine laboratory parameters included haematology, serum chemistry and urinalysis.

Time frame:
At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).
Reported as:
Number · participants
Clinically Significant Abnormal Changes in Routine Laboratory Parameters Between Baseline and the Completion Visit.
participantsIgPro20
Haematology3
Serum Chemistry1
Urinalysis0
SecondaryRate, Severity and Relatedness of Any Adverse Events (AEs) Per Infusion

The rate of AEs was the number of AEs over the number of infusions administered. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.

Time frame:
Up to 42 months
Reported as:
Number · AEs per infusion
Rate, Severity and Relatedness of Any Adverse Events (AEs) Per Infusion
AEs per infusionIgPro20
Total AEs0.0936
Mild AEs0.0685
Moderate AEs0.0231
Severe AEs0.0020
At least possibly related AEs0.0026
Serious AEs0.0033
At least possibly related and serious AEs0

Adverse events

Collected over AEs were collected for the duration of the study, up to 42 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20—14/40 (35%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventIgPro20
Pneumonia bacterialInfections and infestations5/40
ConcussionInjury, poisoning and procedural complications1/40
Spinal column injuryInjury, poisoning and procedural complications1/40
Abdominal painGastrointestinal disorders1/40
FractureInjury, poisoning and procedural complications1/40
Coeliac diseaseGastrointestinal disorders1/40
DiarrhoeaGastrointestinal disorders1/40
Thrombocytopenic purpuraBlood and lymphatic system disorders1/40
PneumoniaInfections and infestations1/40
DyspnoeaRespiratory, thoracic and mediastinal disorders1/40
Most frequent other events
Showing 10 of 49
Most frequent other events
EventIgPro20
BronchitisInfections and infestations21/40
Upper respiratory tract infectionInfections and infestations18/40
SinusitisInfections and infestations13/40
NasopharyngitisInfections and infestations12/40
CoughRespiratory, thoracic and mediastinal disorders11/40
RhinitisInfections and infestations9/40
Febrile infectionInfections and infestations6/40
ArthralgiaMusculoskeletal and connective tissue disorders6/40
Acute sinusitisInfections and infestations5/40
PharyngitisInfections and infestations5/40

Baseline characteristics

Age, Customized
Age, Customized(participants)IgPro20
2 to < 12 years15
12 to < 16 years4
16 to < 65 years21
≥ 65 years0
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20
Female12
Male28
08

Study locations

13 sites
  • Study Site
    Paris, 75743, France
  • Study Site
    Berlin, 13353, Germany
  • Study Site
    Freiburg, 79095, Germany
  • Study Site
    Leipzig, 04129, Germany
  • Study Site
    Mainz, 55131, Germany
  • Study Site
    Warsaw, Poland
  • Study Site
    Cluj-Napoca, 400162, Romania
  • Study Site
    Timisoara, 300011, Romania
  • Study Site
    Barcelona, 08036, Spain
  • Study Site
    Sevilla, 41013, Spain
  • Study Site
    Göteborg, 41685, Sweden
  • Study Site
    Bern, 3010, Switzerland
  • Study Site
    London, EC1A7BE, United Kingdom
09

References and documents

Publications

  • Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL. Long-term efficacy, safety, and tolerability of Hizentra(R) for treatment of primary immunodeficiency disease. Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26. PubMed 24412910 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2008
First posted
Sep 12, 2008
Start
Aug 2008
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Jan 25, 2013
Last update
Apr 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00751621
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Sep 12, 2008
Start date
Aug 2008
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jan 25, 2013
Last update
Apr 2, 2014

Study contacts

Program Director, Clinical R&D
study director · CSL Behring

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion